Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 27, 2026, 5:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–23 of 23 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Nasal Nitric Oxide Measurement Clear all
Completed Phase 1Phase 2 Interventional Results available

Safety and Tolerability of Inhaled Nitric Oxide in Patients With Cystic Fibrosis

NCT00570349
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Nitric Oxide for Inhalation, Nitrogen
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
12 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 12, 2019 · Synced Sep 27, 2026, 5:30 AM EDT
Recruiting Not applicable Interventional

Utility of PCD Diagnostics to Improve Clinical Care

NCT03704207
View directory record Official record
Conditions
Primary Ciliary Dyskinesia
Interventions
nNO testing
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
1 Year and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 27, 2026, 5:30 AM EDT
Not listed Phase 2 Interventional

A Study to Assess Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis

NCT05747508
View directory record Official record
Conditions
Pulmonary Fibrosis, Pulmonary Hypertension
Interventions
INOpulse®, Placebo, Long Term Follow Up
Combination Product
Lead sponsor
Bellerophon
Industry
Eligibility
18 Years to 85 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
23
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2023 · Synced Sep 27, 2026, 5:30 AM EDT
Completed Phase 1Phase 2 Interventional

Sildenafil for PNTM Infection

NCT01853540
View directory record Official record
Conditions
Nontuberculous Mycobacterial Infection
Interventions
Sildenafil
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 24, 2015 · Synced Sep 27, 2026, 5:30 AM EDT
Terminated Phase 3 Interventional

A Study to Assess Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Fibrosis at Risk for Pulmonary Hypertension

NCT03267108
View directory record Official record
Conditions
Pulmonary Fibrosis, Pulmonary Hypertension
Interventions
INOpulse®, Placebo, Open Label Extension
Combination Product
Lead sponsor
Bellerophon Pulse Technologies
Industry
Eligibility
18 Years to 80 Years
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
61
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 49 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2023 · Synced Sep 27, 2026, 5:30 AM EDT
Completed No phase listed Observational

Nasal Nitric Oxide Levels in Eosinophilic Esophagitis (EoE)

NCT01929824
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Oral Nitric Oxide testing
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 29, 2019 · Synced Sep 27, 2026, 5:30 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Levocetirizine Effect on Nasal Nitric Oxide and Nasal Eosinophils in Subjects With Perennial Allergic Rhinitis

NCT00894231
View directory record Official record
Conditions
Perennial Allergic Rhinitis
Interventions
levocetirizine (Xyzal), placebo
Drug
Lead sponsor
AAADRS Clinical Research Center
Other
Eligibility
12 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated Sep 3, 2009 · Synced Sep 27, 2026, 5:30 AM EDT
Completed Phase 2 Interventional

Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)

NCT01457781
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Pulmonary Hypertension
Interventions
Inhaled Nitric Oxide 0.025 mg/kg IBW/hr delivered via INOpulse DS Device, Placebo delivered via INOpulse DS Device, Inhaled nitric oxide 0.075 mg/kg IBW/hr delivered via INOpulse DS Device
Combination Product
Lead sponsor
Bellerophon Pulse Technologies
Industry
Eligibility
16 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
47
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fountain Valley, California + 38 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2023 · Synced Sep 27, 2026, 5:30 AM EDT
Completed Phase 3 Interventional Results available

Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants

NCT00931632
View directory record Official record
Conditions
Bronchopulmonary Dysplasia
Interventions
Inhaled Nitric Oxide, Placebo
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
5 Days to 14 Days
Enrollment
451 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
31
States / cities
Phoenix, Arizona • Loma Linda, California • Orange, California + 26 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2017 · Synced Sep 27, 2026, 5:30 AM EDT
Terminated Phase 3 Interventional Results available

A Study to Assess Pulsed Inhaled Nitric Oxide vs Placebo in Subjects With Mild or Moderate COVID-19

NCT04421508
View directory record Official record
Conditions
COVID-19, Coronavirus, Coronavirus Infection
Interventions
INOpulse, Placebo
Combination Product
Lead sponsor
Bellerophon Pulse Technologies
Industry
Eligibility
18 Years and older
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
17
States / cities
Phoenix, Arizona • San Diego, California • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2023 · Synced Sep 27, 2026, 5:30 AM EDT
Completed Phase 2 Interventional Results available

Nitric Oxide, GeNO Nitrosyl Delivery System

NCT01165047
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Nitric Oxide
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 2, 2024 · Synced Sep 27, 2026, 5:30 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Topical Irrigation Therapy for CRS

NCT02630472
View directory record Official record
Conditions
Rhinitis, Sinusitis
Interventions
Quinine Sulfate, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 12, 2019 · Synced Sep 27, 2026, 5:30 AM EDT
Terminated Phase 2 Interventional

Efficacy and Safety of Inhaled Nitric Oxide (NO) in Cystic Fibrosis (CF) Patients

NCT02498535
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Nitric Oxide 160 ppm
Drug
Lead sponsor
Novoteris, LLC
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
6
States / cities
Garden Grove, California • Los Angeles, California • Columbus, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2021 · Synced Sep 27, 2026, 5:30 AM EDT
Recruiting No phase listed Observational

Use of Nasal Nitric Oxide Testing in Improving Primary Ciliary Dyskinesia Clinical Care

NCT05287022
View directory record Official record
Conditions
Primary Ciliary Dyskinesia
Interventions
Not listed
Lead sponsor
Arkansas Children's Hospital Research Institute
Other
Eligibility
2 Years to 99 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jan 29, 2025 · Synced Sep 27, 2026, 5:30 AM EDT
Completed Phase 3 Interventional Results available

Effect of Nitric Oxide in Cardiac Surgery Patients With Endothelial Dysfunction.

NCT02836899
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
Nitric Oxide, Placebo
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Sep 27, 2026, 5:30 AM EDT
Recruiting Not applicable Interventional

Primary Ciliary Dyskinesia in Adult Bronchiectasis

NCT07566611
View directory record Official record
Conditions
Idiopathic Bronchiectasis
Interventions
Nasal Nitric Oxide Measurement, Nasopharyngeal (Nasal) Samples
Procedure
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 27, 2026, 5:30 AM EDT
Completed Phase 2 Interventional Results available

A Proof of Concept Study of Inhaled Nitric Oxide for Adults With Pulmonary Non-Tuberculous Mycobacterial Infection

NCT03748992
View directory record Official record
Conditions
Nontuberculous Mycobacterium Infection
Interventions
gNO
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
Portland, Oregon • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated May 17, 2021 · Synced Sep 27, 2026, 5:30 AM EDT
Completed Phase 2 Interventional

Study in Subjects With PAH and PH Secondary to IPF Using Inhaled GeNOsyl.

NCT01265888
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Idiopathic Pulmonary Fibrosis
Interventions
Inhaled Nitric Oxide
Drug
Lead sponsor
Geno LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
10
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2016 · Synced Sep 27, 2026, 5:30 AM EDT
Completed Phase 2 Interventional

Two-Part Dose-Confirming Study of Pulsed Inhaled Nitric Oxide in Subjects With WHO Group 3 Pulmonary Hypertension Associated With COPD

NCT01728220
View directory record Official record
Conditions
Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease
Interventions
Inhaled NO delivered via INOpulse DS-C Device, Placebo delivered via INOpulse DS-C Device
Combination Product
Lead sponsor
Bellerophon Pulse Technologies
Industry
Eligibility
40 Years to 80 Years
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
43
States / cities
Jasper, Alabama • Flagstaff, Arizona • Phoenix, Arizona + 35 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2023 · Synced Sep 27, 2026, 5:30 AM EDT
Withdrawn Phase 2 Interventional

iNOPulse for COVID-19

NCT04398290
View directory record Official record
Conditions
COVID-19, Hypoxemia, Hypoxemic Respiratory Failure
Interventions
Inhaled nitric oxide (iNO), Nitrogen gas, Oxygen gas
Drug
Lead sponsor
Roger Alvarez
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 18, 2020 · Synced Sep 27, 2026, 5:30 AM EDT
Enrolling by invitation Phase 2 Interventional

Inhaled Nitric Oxide for Microvascular Dysfunction in Traumatic Brain Injury

NCT05616910
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
inhaled nitric oxide
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 75 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Sep 27, 2026, 5:30 AM EDT
Recruiting No phase listed Observational

Utility of PCD Diagnostics to Improve Clinical Care

NCT05889013
View directory record Official record
Conditions
Primary Ciliary Dyskinesia
Interventions
Nasal Nitric Oxide testing
Device
Lead sponsor
Connecticut Children's Medical Center
Other
Eligibility
2 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 21, 2025 · Synced Sep 27, 2026, 5:30 AM EDT
Withdrawn Phase 3 Interventional

Study to Assess Acute Vasodilation Response of Inhaled Nitric Oxide

NCT02436512
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Inhaled Nitric Oxide
Drug
Lead sponsor
Geno LLC
Industry
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
2
States / cities
Birmingham, Alabama • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 6, 2015 · Synced Sep 27, 2026, 5:30 AM EDT